Abstract PS7-17: Exploring global clinical trial enrollment opportunities in high breast cancer mortality regions
Authors: Jean-Pierre A Blaize, Phillip P Acosta, Isiah Gonzalez, Kristen E Ott, Kate Lathrop
Journal: Cancer Research (2021)

Abstract BACKGROUND Globally, breast cancer is the most commonly diagnosed cancer and the most common cause of cancer death for women. Access to high quality treatment and novel therapies vary significantly based on geographic regions and countries. Mortality rate is considerably higher women in developing and low-income regions compared to high income regions. While many factors contribute to disparities in breast cancer specific outcomes, access to clinical trials provide high quality and evidence-based cancer care. Therefore, we evaluated the availability of breast cancer treatment clinical trial among global regions with the highest breast cancer incidence and related mortality. METHODS In this study, we reviewed clinical trials registered with clinicaltrials.gov and published in 3 high impact journals: The New England Journal of Medicine, Lancet Oncology and the Journal of Clinical Oncology between January 2018 and May 2020. For each trial, the countries from which patients enrolled were captured and compared to the countries in the top 5 regions for highest breast cancer incidence and breast cancer related mortality globally per the GLOBOCAN 2018 estimates. RESULTS A total of 77 clinical trials meet this criteria and enrolled patients in 67 different countries. As most trials enrolled in multiple countries, the enrollment countries for every trial was recorded with a total of 697 enrolled countries in these 77 clinical trials. The global regions with the high breast cancer mortality are Melanesia, Micronesia and Polynesia (Hawaii excluded), Northern Africa, Caribbean and Western Africa. These regions together had only 8 clinical trials that accrued patients during this time frame: one trial in Egypt, 4 in New Zealand and 3 in Puerto Rico. This represents about 1% of country accruals in the trials analyzed (8 of 697). The most frequently enrolling countries were the United States, Canada, Belgium, United Kingdom, Italy, France, Germany, and Spain which have high incidence of breast cancer but lower mortality rates compared to other global regions. CONCLUSIONS High impact breast cancer trials currently enroll patients from areas with high incidence of breast cancer but not from areas with high mortality rates. Barriers that lead to these disparities have not been extensively explored and would be of interest in future studies. Exploring creative ways to bridge this gap, such as working with local governments to help develop clinical centers with ability to run clinical trials and train local medical staff, may be part of an effort to decrease global breast cancer mortality. Citation Format: Jean-Pierre A Blaize, Phillip P Acosta, Isiah Gonzalez, Kristen E Ott, Kate Lathrop. Exploring global clinical trial enrollment opportunities in high breast cancer mortality regions [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS7-17.